マインドウォークHDの適時開示

6-K 1 nomrd.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2025.

Commission File Number: 001-39530

ImmunoPrecise Antibodies Ltd.

Industrious 823 Congress Ave Suite 300 Austin, Texas 78701

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.


Form 20-F ☒	Form 40-F ☐

EXHIBIT INDEX



Exhibit	Description
99.1	Notice of Meeting and Record Date dated August 1, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	IMMUNOPRECISE ANTIBODIES LTD.
Date: August 1, 2025

	By:	/s/ Jennifer Bath
	Name:	Jennifer Bath
	Title:	President and Chief Executive Officer

EX-99.1 2 ipa-ex99_1.htm EX-99.1 EX-99.1

ImmunoPrecise Antibodies Ltd.

3204-4464 Markham Street

Victoria, BC, Canada V8Z 7X8

PH: +1 (250) 483-0308

Website: www.ipatherapeutics.com Email: info@ipatherapeutics.com


Date: August 1, 2025
To: All Canadian Securities Regulatory Authorities NASDAQ Exchange
Subject: IMMUNOPRECISEANTIBODIES LTD.
Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:
Meeting Type : Annual General Meeting Record Date for Notice of Meeting : August 27, 2025 Record Date for Voting (if applicable) : August 27, 2025 Beneficial Ownership Determination Date: August 27, 2025 Meeting Date : October 9, 2025 Meeting Location (if available) : Virtual Meeting Issuer sending proxy related materials directly to NOBO: No Issuer paying for delivery to OBO: No Notice and Access (NAA) Requirements: NAA for Beneficial Holders No NAA for Registered Holders No
Voting Security Details:
Description CUSIP Number ISIN COMMON 45257F200 CA45257F2008

Sincerely, IMMUNOPRECISEANTIBODIES LTD.